Regeneron Pharmaceuticals, Inc. (BIT:1REGN)

Italy flag Italy · Delayed Price · Currency is EUR
650.40
-11.20 (-1.69%)
Last updated: Feb 10, 2026, 4:20 PM CET
Market Cap65.10B -7.2%
Revenue (ttm)12.22B +1.0%
Net Income3.84B +2.1%
EPS35.33 +8.2%
Shares Outn/a
PE Ratio16.97
Forward PE15.65
Dividend3.14 (0.48%)
Ex-Dividend DateNov 19, 2025
Volume2
Average Volume9
Open652.20
Previous Close661.60
Day's Range650.40 - 652.20
52-Week Range418.00 - 697.00
Betan/a
RSI52.72
Earnings DateJan 30, 2026

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines to treat various diseases worldwide. The company develops product candidates to treat eye, allergic and inflammatory, cardiovascular, metabolic, neurological, infectious, and rare diseases; and cancer, hematologic conditions. It also offers EYLEA injections for wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; retinopathy of prematurity; Dupixent ... [Read more]

Industry Pharmaceutical Preparations
Founded 1988
Employees 15,222
Stock Exchange Borsa Italiana
Ticker Symbol 1REGN
Full Company Profile

Financial Performance

In 2025, Regeneron Pharmaceuticals's revenue was $14.34 billion, an increase of 0.99% compared to the previous year's $14.20 billion. Earnings were $4.50 billion, an increase of 2.09%.

Financial numbers in USD Financial Statements